Histrelin

Revision as of 19:57, 27 September 2011 by WikiBot (talk | contribs) (Protected "Histrelin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.


Histrelin
Clinical data
Pregnancy
category
  • US: X (Contraindicated)
Routes of
administration
Subcutaneous implant
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability92%
Protein binding70%
MetabolismHepatic
Elimination half-life4 hours
ExcretionUndetermined
Identifiers
CAS Number
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC66H86N18O12
Molar mass1323.5 g/mol

WikiDoc Resources for Histrelin

Articles

Most recent articles on Histrelin

Most cited articles on Histrelin

Review articles on Histrelin

Articles on Histrelin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Histrelin

Images of Histrelin

Photos of Histrelin

Podcasts & MP3s on Histrelin

Videos on Histrelin

Evidence Based Medicine

Cochrane Collaboration on Histrelin

Bandolier on Histrelin

TRIP on Histrelin

Clinical Trials

Ongoing Trials on Histrelin at Clinical Trials.gov

Trial results on Histrelin

Clinical Trials on Histrelin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Histrelin

NICE Guidance on Histrelin

NHS PRODIGY Guidance

FDA on Histrelin

CDC on Histrelin

Books

Books on Histrelin

News

Histrelin in the news

Be alerted to news on Histrelin

News trends on Histrelin

Commentary

Blogs on Histrelin

Definitions

Definitions of Histrelin

Patient Resources / Community

Patient resources on Histrelin

Discussion groups on Histrelin

Patient Handouts on Histrelin

Directions to Hospitals Treating Histrelin

Risk calculators and risk factors for Histrelin

Healthcare Provider Resources

Symptoms of Histrelin

Causes & Risk Factors for Histrelin

Diagnostic studies for Histrelin

Treatment of Histrelin

Continuing Medical Education (CME)

CME Programs on Histrelin

International

Histrelin en Espanol

Histrelin en Francais

Business

Histrelin in the Marketplace

Patents on Histrelin

Experimental / Informatics

List of terms related to Histrelin

Histrelin acetate is a nonapeptide analog of gonadotropin-releasing hormone (GnRH) with added potency.[1] When present in the bloodstream, it acts on particular cells of the pituitary gland called gonadotropes. Histrelin stimulates these cells to release luteinizing hormone and follicle-stimulating hormone. Thus it is considered a gonadotropin-releasing hormone agonist or GnRH agonist.

Histrelin is marketed by Indevus Pharmaceuticals under the brand names Vantas and Supprelin LA.

Pharmacology

In a process known as downregulation, daily stimulation of pituitary gonadotropes causes them to become desensitized to the effects of histrelin. As a consequence, levels of LH and FSH fall after a short period of time. From that point forward, as long as histrelin is administered, the levels of LH and FSH in the blood remain low.

This prolonged lowering of LH and FSH levels is the rationale for therapy using GnRH agonists. Since LH and FSH stimulate the gonads to produce estrogens and androgens in females and males respectively, histrelin can effectively be used to decrease the sex steroids in the blood of patients.

Indications

Histrelin is used to treat hormone-sensitive cancers of the prostate in men and uterine fibroids in women. In addition, histrelin has been proven to be highly effective in treating central precocious puberty in children.[2][3]

It is available as a daily intramuscular injection. Histrelin is also available in a 12-month subcutaneous implant (Vantas) for the palliative treatment of advanced prostate cancer. A 12-month subcutaneous implant (Supprelin LA) for central precocious puberty (CPP) was approved on May 3, 2007 by the U.S. Food and Drug Administration.

References

  1. Histrelin acetate (Vantas®) - New Drug Bulletins
  2. Histrelin consumer information
  3. Eugster, Erica A. (2007). "Efficacy and Safety of Histrelin Subdermal Implant in Children with Central Precocious Puberty: A Multicenter Trial". J Clin Endocrinol Metab. 92 (5): 1697–1704. doi:10.1210/jc.2006-2479. Retrieved 2007-10-17. Unknown parameter |coauthors= ignored (help)

Template:SIB Template:Sex hormones Template:Pituitary and hypothalamic hormones and analogues


Template:WikiDoc Sources